^
    Back
    Association details:
    Biomarker:HR negative + PD-L1 expression
    Cancer:HER2 Negative Breast Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    HER2 Negative Breast Cancer: Invasive Breast Cancer…ADDITIONAL TARGETED THERAPIES AND ASSOCIATED BIOMARKER TESTING FOR RECURRENT OR STAGE IV (m1) DISEASE…HR-negative/HER2-negative…PD-L1 expression…atezolizumab+Albumin-bound paclitaxel...
    Secondary therapy:
    albumin-bound paclitaxel